cytisine has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bancroft, EA; Chilukuri, S; Cude, B; Garcia, JA; Hook, M; Pandey, G; Salem, NA; Srinivasan, R; Storey, S; Zarate, SM | 1 |
| Abin-Carriquiry, JA; Cassels, BK; Costa, G; Dajas, F; Rebolledo-Fuentes, M; Urbanavicius, J; Wonnacott, S | 1 |
2 other study(ies) available for cytisine and Parkinsonian Disorders
| Article | Year |
|---|---|
Cytisine is neuroprotective in female but not male 6-hydroxydopamine lesioned parkinsonian mice and acts in combination with 17-β-estradiol to inhibit apoptotic endoplasmic reticulum stress in dopaminergic neurons.
Topics: Activating Transcription Factor 6; Alkaloids; Animals; Apoptosis; Azocines; Behavior, Animal; Dopaminergic Neurons; Endoplasmic Reticulum Stress; Estradiol; Female; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Primary Cell Culture; Quinolizines; Sex Characteristics; Substantia Nigra; Sympatholytics; Transcription Factor CHOP; Tyrosine 3-Monooxygenase | 2021 |
In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: implications for Parkinson's Disease.
Topics: Alkaloids; Animals; Antiparkinson Agents; Azocines; Bridged-Ring Compounds; Disease Models, Animal; Dopamine; Male; Microdialysis; Neostriatum; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Quinolizines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Receptors, Presynaptic; Substantia Nigra | 2008 |